Cryptococcal therapies and drug targets: the old, the new and the promising
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Half a century after the introduction of Amphotericin B the management of cryptococcosis remains unsatisfactory. The disease, caused primarily by the two fungal species Cryptococcus neoformans and Cryptococcus gattii, remains responsible for considerable morbidity and mortality despite standard medical care. Current therapeutic options are limited to Amphotericin B, azoles and 5-flucytosine. However, this organism has numerous well-characterized virulence mechanisms that are amenable to pharmacological interference and are thus potential therapeutic targets. Here, we discuss existing approved antifungal drugs, resistance mechanisms to these drugs and non-standard antifungal drugs that have potential in treatment of cryptococcosis, including immunomodulatory strategies that synergize with antifungal drugs, such as cytokine administration or monoclonal antibodies. Finally, we summarize attempts to target well-described virulence factors of Cryptococcus, the capsule or fungal melanin. This review emphasizes the pressing need for new therapeutic alternatives for cryptococcosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Rodrigues, M. L., Nakayasu, E. S., Oliveira, D. L., Nimrichter, L., Nosanchuk, J. D., Almeida, I. C., & Casadevall, A. (2008) · Eukaryotic Cell · doi:10.1128/ec.00370-07 · Cited by 558
Self-citationUrease as a Virulence Factor in Experimental Cryptococcosis
Cox, G. M., Mukherjee, J., Cole, G. T., Casadevall, A., & Perfect, J. R. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.443-448.2000 · Cited by 522
Self-citationJarvis, J. N., Bicanic, T., Loyse, A., Namarika, D., Jackson, A., Nussbaum, J. C., Longley, N., Muzoora, C., Phulusa, J., Taseera, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit794 · Cited by 367 · cited 2×
“© 2016 John Wiley & Sons Ltd, Cellular Microbiology, 18, 792–799 IFN-γ Interferon-γ is a key cytokine in cryptococcosis such that in human patients a strong IFN-γ response indicates a good prognosis (Jarvis et al., 2012; Jarvis et al., 2014).”
BackgroundMelanin-lacking mutants of Cryptococcus neoformans and their virulence for mice
Kwon-Chung, K. J., Polacheck, I., & Popkin, T. J. (1982) · Journal of Bacteriology · doi:10.1128/jb.150.3.1414-1421.1982 · Cited by 327 · cited 1×
“Their use in clinical trials phase I (Larsen et al., 2005) was promising.”
BackgroundHarnessing calcineurin as a novel anti-infective agent against invasive fungal infections.
Steinbach, W. J., Reedy, J. L., Cramer, R. A., Perfect, J. R., & Heitman, J. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1680 · Cited by 313
Casadevall, A., Cleare, W., Feldmesser, M., Glatman-Freedman, A., Goldman, D. L., Kozel, T. R., Lendvai, N., Mukherjee, J., Pirofski, L.-A., Rivera, J., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1437 · Cited by 298 · cited 1×
“The lack of Ab response can be overcome by use of polysaccharide–conjugate vaccines, which elicit strong antibody responses and allowed the isolation of several anti-capsule mAb from mice (Casadevall et al., 1992; Casadevall et al., 1998; Shapiro et al., 2002).”
BackgroundSelf-citationJarvis, J. N., Meintjes, G., Rebe, K., Williams, G. N., Bicanic, T., Williams, A., Schutz, C., Bekker, L.-G., Wood, R., & Harrison, T. S. (2012) · AIDS · doi:10.1097/qad.0b013e3283536a93 · Cited by 290 · cited 1×
“High-throughput screens generated at least two new classes of compounds with anticryptococcal activity in vitro: hydroxyaldimines or Schiff bases, (Magalhães et al., 2013) and aminiothiazioles (Khalil et al., 2015).”
Zhai, B., Wu, C., Wang, L., Sachs, M. S., & Lin, X. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00212-12 · Cited by 205 · cited 8×
“Severe toxicity of AmpB was a significant problem pushing the development of novel liposomal formulations which succeed in improving AmpB safety.”
BackgroundInfluentialRecombinant Interferon‐γ1b as Adjunctive Therapy for AIDS‐Related Acute Cryptococcal Meningitis
Pappas, P. G., Bustamante, B., Ticona, E., Hamill, R. J., Johnson, P. C., Reboli, A., Aberg, J., Hasbun, R., & Hsu, H. H. (2004) · The Journal of Infectious Diseases · doi:10.1086/420829 · Cited by 202 · cited 1×
“The first found a trend towards better clinical outcome and earlier CNS sterilization but no differences in survival (Pappas et al., 2004).”
Result
Cited by
The antifungal pipeline: a reality check
Perfect, J. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.46 · Cited by 866
Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases
Kak, G., Raza, M., & Tiwari, B. K. (2018) · Biomolecular Concepts · doi:10.1515/bmc-2018-0007 · Cited by 617
The Still Underestimated Problem of Fungal Diseases Worldwide
Almeida, F., Rodrigues, M. L., & Coelho, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00214 · Cited by 445
Self-citationMechanisms of Pulmonary Escape and Dissemination by Cryptococcus neoformans
Denham, S., & Brown, J. (2018) · Journal of Fungi · doi:10.3390/jof4010025 · Cited by 67
“neoformans, melanin pigment is exported to the cell wall [105], where it provides protection against ultraviolet radiation and oxidative damage [106,107].”
BackgroundSynergistic and antagonistic drug interactions in the treatment of systemic fungal infections
Wambaugh, M. A., Denham, S. T., Ayala, M., Brammer, B., Stonhill, M. A., & Brown, J. C. (2020) · eLife · doi:10.7554/elife.54160 · Cited by 65
“To date, there are only four classes of antifungals, which primarily target the fungal cell envelope (cell wall and plasma membrane) (Coelho and Casadevall, 2016; Odds et al., 2003; Pianalto and Alspaugh, 2016; Scorzoni et al., 2017).”
Background
Metadata
- Authors
- Coelho, C., & Casadevall, A.
- Venue
- Cellular Microbiology
- Publisher
- Wiley
- Published
- 2016-04-08
- Volume
- 18
- Issue
- 6
- Pages
- 792-799
- ISSN
- 1462-5814 (ISSN-L)
- OpenAlex
- W2301515547
- Cited by
- 95
- References
- 22
- FWCI
- 11.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cryptococcal therapies and drug targets: the old, the new and the promising. https://app.cochat.ai/papers/10.1111/cmi.12590
- The paper
- Coelho, C., & Casadevall, A. (2016). Cryptococcal therapies and drug targets: the old, the new and the promising. Cellular Microbiology. https://doi.org/10.1111/cmi.12590
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.